Wall Street Analysts Are Bullish on Top Healthcare Picks

view original post

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Laboratories (ABTResearch Report), Halozyme (HALOResearch Report) and Ventyx Biosciences (VTYXResearch Report) with bullish sentiments.

Abbott Laboratories (ABT)

In a report released yesterday, Travis Steed from Bank of America Securities maintained a Buy rating on Abbott Laboratories, with a price target of $133.00. The company’s shares closed last Wednesday at $103.23.

According to TipRanks.com, Steed is a 4-star analyst with an average return of 6.4% and a 63.6% success rate. Steed covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Zimmer Biomet Holdings, and Edwards Lifesciences.

Currently, the analyst consensus on Abbott Laboratories is a Strong Buy with an average price target of $127.75, which is a 24.1% upside from current levels. In a report issued on May 30, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $121.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Halozyme (HALO)

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Halozyme, with a price target of $48.00. The company’s shares closed last Wednesday at $45.65, close to its 52-week high of $46.16.

According to TipRanks.com, Bansal is a 4-star analyst with an average return of 8.3% and a 58.9% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., BioMarin Pharmaceutical, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Halozyme is a Strong Buy with an average price target of $52.29, representing a 17.3% upside. In a report issued on May 22, H.C. Wainwright also reiterated a Buy rating on the stock with a $50.00 price target.

Ventyx Biosciences (VTYX)

Wells Fargo analyst Derek Archila maintained a Buy rating on Ventyx Biosciences yesterday and set a price target of $16.00. The company’s shares closed last Wednesday at $5.28, close to its 52-week low of $1.87.

According to TipRanks.com, Archila is a 4-star analyst with an average return of 5.6% and a 40.2% success rate. Archila covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, Monte Rosa Therapeutics, and Apellis Pharmaceuticals.

Currently, the analyst consensus on Ventyx Biosciences is a Moderate Buy with an average price target of $12.67, implying a 157.0% upside from current levels. In a report issued on May 28, LifeSci Capital also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ABT: